Status and influencing factors of symptom burden of colorectal cancer patients during chemotherapy
Objective:To analyze status and influencing factors of symptom burden in patients with colorectal cancer during chemotherapy. Methods:The clinical data of 75 patients with colorectal cancer who received chemotherapy in this hospital from January 2022 to January 2023 were retrospectively analyzed. The Chinese version of the M. D. Anderson symptom inventory (MDASI-C) was used to assess the status of symptom burden during chemotherapy in the patients with colorectal cancer. The MDASI-C scores of the patients with different baseline data were compared. The influencing factors of symptom burden in the patients with colorectal cancer during chemotherapy were analyzed using multiple linear regression analysis. Results:The average MDASI-C score of the 75 patients with colorectal cancer during chemotherapy was (70.36±6.32). There was no significant difference in the MDASI-C score among the colorectal cancer patients with different gender,age,education level,marital status and social support (P>0.05). There were statistically significant differences in the MDASI-C scores among the colorectal cancer patients with different course of disease,degree of tumor differentiation,economic status,clinical stage,number of chemotherapy,and grade of toxic and side effects (P<0.05). The multiple linear regression analysis showed that the course of disease ≥ 1 year,low degree of tumor differentiation,poor economic status,clinical stage Ⅲ-Ⅳ,chemotherapy ≥ 3 times,and grade of toxic and side effects Ⅲ-Ⅳ were all risk factors for heavy symptom burden in the patients with colorectal cancer during chemotherapy (P<0.05). Conclusions:The course of disease ≥ 1 year,low degree of tumor differentiation,poor economic status,clinical stage Ⅲ-Ⅳ,chemotherapy ≥ 3 times,and grade of toxic and side effects Ⅲ-Ⅳ are the risk factors for the heavy symptom burden of the colorectal cancer patients during chemotherapy.
万方数据
维普
